


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on May 7, 2008.



Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121
Patent Application
Docket No. ARS-122

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Regina M. DeBerry
Art Unit : 1647
Applicants : Christine Power, Yan Lavrovsky
Serial No. : 10/570,122
Filed : February 28, 2006
Conf. No. : 7430
For : Treatment of Fibrotic Disease

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121 AND
SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

In response to the written Restriction Requirement dated April 7, 2008 in the above-identified patent application, Applicants hereby elect to prosecute the invention of Group II (claims 25-32, 36, 37 and 43, drawn in part to a method for treating/preventing a fibrotic disease comprising administering to a patient a polypeptide and an interferon), without traverse. As the species, Applicants hereby elect SEQ ID NO: 2.

Prior to examination, Applicants respectfully request that the subject application be amended as follows: